about
Reduced histone deacetylase 7 activity restores function to misfolded CFTR in cystic fibrosisDirected evolution of a histone acetyltransferase--enhancing thermostability, whilst maintaining catalytic activity and substrate specificity.Learning therapeutic lessons from metastasis suppressor proteins."Shock and kill" effects of class I-selective histone deacetylase inhibitors in combination with the glutathione synthesis inhibitor buthionine sulfoximine in cell line models for HIV-1 quiescence.Pharmacology of epigenetics in brain disordersFunctional characterization of Candida albicans Hos2 histone deacetylase.Epigenetic drugs against cancer: an evolving landscape.Selective histonedeacetylase inhibitor M344 intervenes in HIV-1 latency through increasing histone acetylation and activation of NF-kappaBSIRT1, p66(Shc), and Set7/9 in vascular hyperglycemic memory: bringing all the strands togetherCellular conditioning with trichostatin A enhances the anti-stress response through up-regulation of HDAC4 and down-regulation of the IGF/Akt pathway.Metalloproteases as potential therapeutic targets in arthritis treatment.Epigenetic changes: a common theme in acute myelogenous leukemogenesisEpigenetics in atherosclerosis and inflammation.HIV-1 regulation of latency in the monocyte-macrophage lineage and in CD4+ T lymphocytes.Histone deacetylase inhibitors (HDACIs). Structure--activity relationships: history and new QSAR perspectives.Chemical biology of histone acetyltransferase natural compounds modulators.Developmental mechanisms involved in the primary prevention of atherosclerosis and cardiovascular disease.Screening for compounds that modulate epigenetic regulation of the transcriptome: an overview.Small-molecule chromatin-modifying agents: therapeutic applications.Achieving a cure for HIV infection: do we have reasons to be optimistic?Epigenetic Treatment of Neuropsychiatric Disorders: Autism and Schizophrenia.Novel cinnamyl hydroxyamides and 2-aminoanilides as histone deacetylase inhibitors: apoptotic induction and cytodifferentiation activity.Bioprotective carnitinoids: lipoic acid, butyrate, and mitochondria-targeting to treat radiation injury: mitochondrial drugs come of age.Epigenetic changes in colorectal cancer
P2860
Q24615395-BDFC1B1C-F2C5-405E-BBEB-28FC28CD11FFQ30373030-E8A578C1-FDCB-47B6-A423-B69BD508F0AAQ30435922-2AFD5D6A-3951-4016-B019-1EB46C116063Q30488246-1EAEB885-29A5-4F81-85BD-B12F81B0E502Q33673025-CECF649F-F9C4-4CE6-BF66-9CE05E0258D7Q33950770-64BACC53-48EB-4B6E-A070-912CED936979Q34431964-6F5B1CB6-92ED-486D-91CC-941932C8BF74Q34482017-40A1838C-8B26-4BB3-B1E7-1DC2EA0D9EC9Q36867464-8C1D6D74-9E85-4BCC-9294-7CDF399E1651Q36952764-02B328A0-A2AE-4510-9A14-DE4A8A2E1649Q37030862-D175736E-0BC4-499F-9ADC-28B04603E8CFQ37116613-BD467A19-BD71-4ED3-807F-E9D5D000B02FQ37310578-7536C9DF-0696-4600-87B6-5A1DA5567C2BQ37607912-6F8D5FEC-65D8-4AAE-B7AC-04A003AF30E5Q37693855-3ED18C28-4C0B-44AE-9BCA-51AB6AE28C20Q37825449-1DF750C4-9466-4931-AC4E-BB9859DC5BCFQ37827406-5FE5D089-8BA5-4F14-88A9-763F1F99E6A2Q37946239-2B20B2DF-AF69-4A6D-8DC3-5B91B3943D04Q37961728-4D1E59ED-54E2-4DB9-9541-D72E38599666Q37980423-A2D4A880-4EF9-4F23-B124-43D1A000F8BFQ38743021-FC436917-B3E9-4FB0-AD92-83E9C2A38459Q39581390-F4D8EB68-2124-4F46-8F8D-F812BDF65E8DQ41953858-673320BD-FBD4-480B-89A5-A036AF9394CBQ41973340-890E0598-05C9-48A5-B640-115340F68232
P2860
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
The therapeutic uses of chromatin-modifying agents.
@en
type
label
The therapeutic uses of chromatin-modifying agents.
@en
prefLabel
The therapeutic uses of chromatin-modifying agents.
@en
P2860
P1476
The therapeutic uses of chromatin-modifying agents.
@en
P2860
P304
P356
10.1517/14728222.11.6.835
P407
P577
2007-06-01T00:00:00Z